Airway hyperresponsiveness to bradykinin induced by allergen challenge in actively sensitised Brown Norway rats.
The mechanism(s) of bradykinin-induced bronchoconstriction was investigated in the Brown Norway (BN) rat model of allergic asthma. Bronchoconstrictor responses to i.v. bradykinin in BN rats were maximally augmented 24 h following challenge with allergen and declined at later time points. Histological evaluation of the inflammatory status of the lungs after ovalbumin (OA) challenge showed a marked inflammatory response, which was maximal at 24 h and declined thereafter. However, pretreatment with budesonide did not inhibit the augmented bronchoconstrictor response to bradykinin 24 h after allergen challenge. The selective B1 receptor agonist, Lys-[desArg9]-BK had no bronchoconstrictor effects, whereas the selective B2 receptor antagonist, HOE 140, abolished the response to bradykinin in OA-challenged animals. The augmented response to bradykinin was not affected by methysergide, indomethacin, disodium cromoglycate, iralukast, the 5-lipoxygenase inhibitor, CGS8515, or the NK2 receptor antagonist, SR48968. It was, however, partially inhibited by atropine both in saline- and OA-challenged animals. Pretreatment with captopril and thiorphan markedly potentiated responses to bradykinin both in saline- and OA-challenged animals. Thus, augmentation of the bronchoconstrictor response to bradykinin occurs in actively sensitised BN rats 24 h after challenge with OA and is associated with marked pulmonary inflammation. The response is entirely B2 receptor mediated and approximately 50% of the response is cholinergic. However, mast cell activation, the products of the cyclooxygenase or 5-lipoxygenase pathways and tachykinins are not involved. Peptidase inhibition mimics the effect of allergen challenge on the bronchoconstrictor response to bradykinin and it remains possible that the mechanism of the augmented response to bradykinin following allergen challenge involves downregulation of peptidase activity as a consequence of the inflammatory response.
Ellis
K M
KM
Research Department, Novartis Institute for Biomedical Research, 4002 Basel, Switzerland.
Cannet
C
C
Mazzoni
L
L
Fozard
J R
JR
D000241:Adenosine / Q000494:pharmacology; D058665:Adrenergic beta-1 Receptor Agonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000502:physiology; D001920:Bradykinin / Q000494:pharmacology / Q000502:physiology*; D016535:Bronchial Hyperreactivity / Q000276:immunology* / Q000503:physiopathology; D016084:Bronchoconstriction / Q000187:drug effects*; D016085:Bronchoconstrictor Agents / Q000494:pharmacology; D004195:Disease Models, Animal; D010450:Endopeptidases / Q000502:physiology; D008168:Lung / Q000473:pathology; D008297:Male; D008407:Mast Cells / Q000502:physiology; D016210:Methacholine Chloride / Q000494:pharmacology; D010047:Ovalbumin / Q000276:immunology; D051381:Rats; D011914:Rats, Inbred BN; D011976:Receptors, Muscarinic / Q000502:physiology; D015320:Tachykinins / Q000502:physiology
D058665:Adrenergic beta-1 Receptor Agonists; D058672:Adrenergic beta-2 Receptor Antagonists; D016085:Bronchoconstrictor Agents; D011976:Receptors, Muscarinic; D015320:Tachykinins; D016210:Methacholine Chloride; D010047:Ovalbumin; D001094:Arachidonate 5-Lipoxygenase; D010450:Endopeptidases; D000241:Adenosine; D001920:Bradykinin